Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6383–6388 | Cite as

Susceptibility to hepatocellular carcinoma in the Chinese population—associations with interleukin-6 receptor polymorphism

  • Yan Deng
  • Meng Li
  • Jian Wang
  • Li Xie
  • Taijie Li
  • Yu He
  • Qinghua Lu
  • Ruolin Li
  • Aihua Tan
  • Xue Qin
  • Shan Li
Research Article

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly malignant diseases in the world. Genetic variations in cytokine genes may have an effect on the immune and inflammatory responses which are associated with HBV-HCC. The interleukin-6 (IL-6) receptor is known to be mainly expressed by hepatocytes, neutrophils, monocytes/macrophages, and some lymphocytes, which have been used as prognostic markers in a variety of inflammatory diseases such as rheumatoid arthritis, asthma, and Crohn’s disease. To determine the association of IL-6 receptor (IL-6R) polymorphism with the risk of hepatocellular carcinoma (HCC) development in the Chinese population, a hospital based case–control study was designed consisting of 192 subjects with HCC and 192 healthy control subjects. Our results revealed no risk associations (p = 0.064) with rs6684439 CT genotypes. However, rs6684439 TT genotypes were associated with a significantly decreased risk of HBV-related HCC compared with the CC genotype (odds ratio (OR) = 0.469, 95 % confidence interval (CI) 0.228–0.967, p = 0.040). The data also revealed that subjects with the T allele appeared to have a lower susceptibility to HBV-related HCC than those with the C allele (OR = 0.657, 95 % CI 0.476–0.907, p = 0.011). The present study supports the view that variants in the rs6684439 SNP of IL-6R is associated with a lower risk of HBV-related HCC, and this could provide valuable clues to understanding the mechanisms underlying susceptibility to this malignant disease. Replication and further functional studies should be carried out in the future using larger samples.

Keywords

Hepatocellular carcinoma IL-6 receptor SNP 

Notes

Acknowledgments

This study was supported by the Guangxi Natural Science Foundation(2012GXNSFBA053117).

References

  1. 1.
    Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211.CrossRefPubMedGoogle Scholar
  2. 2.
    Verhoef C, Visser O, de Man RA, et al. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns. Eur J Cancer. 2004;40(10):1530–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–87.CrossRefPubMedGoogle Scholar
  4. 4.
    Jang JW, Oh BS, Kwon JH, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60(3):686–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. FASEB J Off Publ Fed Am Soc Exp Biol. 1997;11(6):457–65.Google Scholar
  6. 6.
    Phoa N, Epe B. Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis. 2002;23(3):469–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Carbone G, Wilson A, Diehl SA, et al. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci. 2013;9(3):279–88. PMCID: 3596713.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Galicia JC, Tai H, Komatsu Y, et al. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5(6):513–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Hawkins GA, Robinson MB, Hastie AT, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol. 2012;130(2):510–5.e1. PMCID: 3409329.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Revez JA, Bain L, Chapman B, et al. (2013). A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk. Genes Immun.Google Scholar
  12. 12.
    Zhang HY, Feng L, Wu H, et al. (2013). The association of IL-6 and IL-6R gene polymorphisms with chronic periodontitis in a Chinese population. Oral Dis.Google Scholar
  13. 13.
    Anderson DR, Poterucha JT, Mikuls TR, et al. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine. 2013;62(3):395–400.CrossRefPubMedGoogle Scholar
  14. 14.
    Heinz D, Peters M, Prange R, et al. Possible role of human interleukin-6 and soluble interleukin-6 receptor in hepatitis B virus infection. J Viral Hepat. 2001;8(3):186–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang F, Yao S, Zhang M, et al. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2011;15(4):e267–71.Google Scholar
  16. 16.
    Li S, Deng Y, Chen ZP, et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2011;11(8):2083–8.CrossRefGoogle Scholar
  17. 17.
    Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer J Int Cancer. 1996;67(5):620–5.CrossRefGoogle Scholar
  18. 18.
    Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79(3-4):123–30. PMCID: 1994795.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Cheng CW, Su JL, Lin CW, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS ONE. 2013;8(2):e56130. PMCID: 3573054.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Ognjanovic S, Yuan JM, Chaptman AK, et al. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30(5):758–62. PMCID: 2675648.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Rafiq S, Frayling TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 2007;8(7):552–9. PMCID: 2668154.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Jiang CQ, Lam TH, Liu B, et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity (Silver Spring). 2010;18(10):1969–74.CrossRefGoogle Scholar
  23. 23.
    Shimamoto K, Ito T, Ozaki Y, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Ivancso I, Toldi G, Bohacs A, et al. Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy. PLoS ONE. 2013;8(4):e60697. PMCID: 3614899.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Nancey S, Hamzaoui N, Moussata D, et al. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci. 2008;53(1):242–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Soresi M, Giannitrapani L, D'Antona F, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol WJG. 2006;12(16):2563–8.PubMedGoogle Scholar
  27. 27.
    Gu F, Qureshi AA, Niu T, et al. Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res. 2008;18(5):330–5. PMCID: 2643877.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Birmann BM, Tamimi RM, Giovannucci E, et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18(1):282–8. PMCID: 2661109.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yan Deng
    • 1
  • Meng Li
    • 1
  • Jian Wang
    • 1
  • Li Xie
    • 1
  • Taijie Li
    • 1
  • Yu He
    • 1
  • Qinghua Lu
    • 1
  • Ruolin Li
    • 2
  • Aihua Tan
    • 3
  • Xue Qin
    • 1
  • Shan Li
    • 1
  1. 1.Department of Clinical LaboratoryThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Department of Medicine ResearchThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
  3. 3.Department of ChemotherapyThe Affiliated Tumor Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations